Spray-drying encapsulation of microwave-assisted extracted polyphenols from Moringa oleifera: Influence of tragacanth, locust bean, and carboxymethyl-cellulose formulations.

In this work, polyphenols from Moringa oleifera (Mor) leaves were extracted by microwave-assisted extraction (MAE) and encapsulated by spray-drying (SD). Particularly, we explored the influence of tragacanth gum (TG), locust bean gum (LBG), and carboxymethyl-cellulose (CMC) as wall-materials on the physicochemical behavior of encapsulated Mor. Single or combined wall-material treatments (100:00 and 50:50 ratios, and total solid content 1%) were tested. The results showed the wall-material had a significant effect on the process yield (55.7-68.3%), encapsulation efficiency (24.28-35.74%), color (yellow or pale-yellow), total phenolic content (25.17-27.49 mg GAE g-1 of particles), total flavonoid content (23.20-26.87 mg QE g-1 of particles), antioxidant activity (DPPH• = 5.96-6.95 mg GAE g-1; ABTS•+ = 5.61-6.18 mg TE g-1 of particles), and particle size distribution (D50 = 112-1946 nm) of the encapsulated Mor. On the other hand, SEM analysis showed smooth and spherical particles, while TGA and DSC analyses confirmed the encapsulation of bioactive compounds based on the changes in thermal peaks. Finally, XRD analysis showed that the particles have an amorphous behavior. The encapsulated Mor produced with individual TG or CMC demonstrated better properties than those obtained from mixed gums. Thus, TG or CMC might be feasible wall materials for manufacturing encapsulated Mor that conserve the phenolic content and antioxidant activity.

Pharmacological and toxicological investigations of etodolac loaded gum katira microspheres prepared by W1/O/W2 emulsion solvent evaporation technique in rats

ABSTRACT Etodolac is a non-steroidal anti-inflammatory drug (NSAID) and approved by USFDA as a COX2 inhibitor. Although etodolac therapy provides clinical benefits, it is associated with upper gastrointestinal (GI) tract complications also. Etodolac loaded gum Katira microsphere (ELGKM) was prepared by W1/O/W2 emulsion solvent evaporation technique. The gastric irritation properties of orally administered pure etodolac, ELGKM and blank microspheres (without etodolac) were evaluated in experimental rats treated for 6 days. The stomach examination and biochemical investigation of stomach tissue of treated rats indicated that ELGKM formulation remarkably reduced ulcerogenecity as compared to pure etodolac. The anti-inflammatory activities of pure etodolac and ELGKMs were ascertained by the implantation of cotton pellets in rats for 6 days. Based on the results, ELGKMs showed significant anti-inflammatory activities (P<0.01) as compared to control group. The cotton pellets test suggested that ELGKM formulation retained more anti-inflammatory properties among the groups. The hematological changes, biochemical analysis and histopathological studies of subacute toxicity in rats revealed that ELGKM were the effective sustained release formulation in the treatment of chronic pain and inflammation. In conclusion, the physicochemical characterization, pharmacological and toxicological studies suggest that ELGKMs may represent as a potential candidate for sustained drug delivery (10-12 hours) in chronic joint pain related diseases with remarkably diminished gastrointestinal side effects.

Structure of the arabinogalactan from gum tragacanth (Astralagus gummifer).

The polysaccharide obtained by ethanol precipitation from an aqueous solution of gum tragacanth contained arabinogalactan and tragacanthic acid, as well as starch ( approximately 0.6%). GC-MS, NMR, and ESI-MS analyses showed the structure of the arabinogalactan to be even more complex than previously determined, with core structures containing Arap, beta-Araf, and alpha-Galp units, as well as known terminal, and 2-O- and 3-O-substituted alpha-Araf units. Analysis was aided by examination of free, reducing oligosaccharides present in the gum. In addition to maltose, maltotriose, maltotetraose, and maltopentaose, the following were characterized: mixed alpha-Araf (1-->2)-alpha-Araf-(1-->4)-Ara and alpha-Araf-(1-->2)-alpha-Araf-(1-->5)-Ara, which correspond to the side chains of the arabinogalactan, beta-Galp-(1-->4)-beta-Galp-(1-->4)-beta-Galp-(1-->4)-Gal; and a mixture of beta-Galp-(1-->4)-beta-Galp-(1-->4)-Gal and beta-Glcp-(1-->4)-beta-Galp-(1-->4)-beta-Galp-(1-->4)-Gal, which did not resemble side-chain structures of the arabinogalactan. The latter are suggested to be related to tragacanthic acid, which has been previously found to contain beta-Galp nonreducing end-units.